Nymox Pharmaceutical Corp
NYMXF- Exchange
- OTC
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001018735
No open-market purchases or sales by Nymox Pharmaceutical Corp insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $4.21K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Nymox Pharmaceutical Corp as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 1
- 0 vs. Q1 2026
- Shares held
- 35.1K
- 0 (0.0%) vs. Q1 2026
- Total value
- $4.21K
- +$1.75K (+71.4%) vs. Q1 2026
- New holders
- 0
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NYMXF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $4.21K |
| Q1 2026 | 1 | $2.46K |
| Q4 2025 | 1 | $1.41K |
| Q3 2025 | 1 | $2.06K |
| Q2 2025 | 1 | $4.13K |
| Q1 2025 | 2 | $16.0K |
| Q4 2024 | 1 | $3.51K |
| Q3 2024 | 2 | $13.2K |
| Q2 2024 | 1 | $6.67K |
| Q1 2024 | 3 | $48.0K |
| Q4 2023 | 2 | $26.6K |
| Q3 2023 | 5 | $68.3K |
| Q2 2023 | 36 | $287.4K |
| Q1 2023 | 35 | $575.1K |
| Q4 2022 | 37 | $443.7K |
| Q3 2022 | 34 | $494.6K |
| Q2 2022 | 39 | $590.1K |
| Q1 2022 | 40 | $2.25M |
| Q4 2021 | 42 | $2.13M |
| Q3 2021 | 38 | $4.00M |
| Q2 2021 | 51 | $4.03M |
| Q1 2021 | 59 | $13.4M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Nymox Pharmaceutical Corp; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| First Citizens Financial Corp | 35,100 | $4.21K | 0.00% | 00.0% | Unchanged |